Trial Profile
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 06 Feb 2024 Planned End Date changed from 26 Aug 2023 to 12 Dec 2024.
- 01 Sep 2023 Primary endpoint Progression Free Survival) has been met according to results published in the Nature Medicine.
- 01 Sep 2023 Results published in the Nature Medicine